The long-term objective of the proposed research is to elucidate the mechanism and regulatory factors involved in the interactions of proteases of the blood coagulation system with circulating protein inhibitors, and to define the effects of heparin and related compounds on these processes. this should lead to a better understanding of various physiological and pathological aspects of coagulation and will delineate the effects that administration of heparin can produce when utilized in the treatment of thrombotic disorders. The specific reactions to be investigated will be those between thrombin and antithrombin III; Factor Xa and antithrombin III; and Factor Xa and alpha1-Proteinase Inhibitor. A study will be made on the specific effects of heparin on each of these reactions. The actions of heparan sulfate and dermatan sulfate as physiological effectors in promoting the neutralization of procoagulants by antithrombin will also be investigated. Additionally, the possible contribution of glucosyl ceramide to the activity of antithrombin III will be determined. Detailed studies will also be conducted on the location and distribution in high molecular weight heparin, of the oligosaccharide sequences that function as the recognition or binding sites for target proteins. These investigations will include novel procedures involving reactions on matrix-bound heparin and covalently linked fluorescent labels. The binding of heparin with coagulant proteins and inhibitor-proteins, as well as the reactions between coagulant and anticoagulant proteins will be studied by means of fluorescent-labeled components. Fluorescence intensity and polarization techniques will be employed. These investigations are expected to define the relationship between the chain-length of heparin and the binding stoichiometries, equilibrium binding constants, and rates of the abovementioned processes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL016955-12
Application #
3335301
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1977-05-01
Project End
1987-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
12
Fiscal Year
1985
Total Cost
Indirect Cost
Name
New York Medical College
Department
Type
Schools of Medicine
DUNS #
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Leong, J M; Robbins, D; Rosenfeld, L et al. (1998) Structural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 66:6045-8
Lahiri, B; Lai, P S; Pousada, M et al. (1992) Depolymerization of heparin by complexed ferrous ions. Arch Biochem Biophys 293:54-60
Jaikaria, N S; Rosenfeld, L; Khan, M Y et al. (1991) Interaction of fibronectin with heparin in model extracellular matrices: role of arginine residues and sulfate groups. Biochemistry 30:1538-44
Danishefsky, I; Rosenfeld, L; Kuhn, L et al. (1989) Location of specific units in heparin and heparan sulfate. Ann N Y Acad Sci 556:29-35
Rosenfeld, L; Danishefsky, I (1988) Location of specific oligosaccharides in heparin in terms of their distance from the protein linkage region in the native proteoglycan. J Biol Chem 263:262-6
Rosenfeld, L; Danishefsky, I (1986) A fragment of antithrombin that binds both heparin and thrombin. Biochem J 237:639-46
Agarwal, A; Danishefsky, I (1986) Requirement of free carboxyl groups for the anticoagulant activity of heparin. Thromb Res 42:673-80
Radoff, S; Danishefsky, I (1985) Distribution of glucuronic and iduronic acid units in heparin chains. J Biol Chem 260:15106-11
Rosenfeld, L; Radoff, S; Danishefsky, I (1985) The uronic acid composition of anticoagulantly active and inactive heparin. Arch Biochem Biophys 242:574-8